X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.fiercepharma.com/pharma/amgen-stumbled-bristol-myers-touts-kras-confirmatory-trial-win-newly-bought-krazati
https://www.prnewswire.com/news-releases/mirati-therapeutics-receives-positive-opinion-from-chmp-for-krazati-adagrasib-as-a-targeted-treatment-option-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-with-a-krasg12c-mutation-following-a-re-examination-proce-301984690.html
https://www.globenewswire.com//news-release/2023/11/02/2772156/35186/en/Kura-Oncology-and-Mirati-Therapeutics-Enter-into-Clinical-Collaboration-and-Supply-Agreement-to-Evaluate-KO-2806-and-Adagrasib-in-KRAS%E1%B4%B3-%E1%B6%9C-Mutated-NSCLC.html
https://www.onclive.com/view/bazhenova-details-potential-pathways-forward-for-targeting-kras-mutations-in-nsclc
https://ir.mirati.com/press-releases/press-release-details/2023/Mirati-Therapeutics-Provides-Update-on-Regulatory-Review-in-the-European-Union-of-KRAZATI-adagrasib-for-the-Treatment-of-Advanced-Non-Small-Cell-Lung-Cancer-NSCLC-with-a-KRAS-G12C-Mutation/default.aspx
https://www.fiercepharma.com/pharma/miratis-kras-drug-beat-estimates-first-full-quarter-keytruda-combo-strategy-remains-unclear
https://ir.mirati.com/press-releases/press-release-details/2022/Mirati-announces-Adagrasib-KRAZATI-Receives-Breakthrough-Therapy-Designation-from-FDA-for-Patients-with-Advanced-KRAS-Mutated-Colorectal-Cancer-and-NEJM-Publishes-Phase-1b2-Data-from-Adagrasib-With-or-Without-Cetuximab-in-Colorectal-Cancer/default.aspx
https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-us-fda-accelerated-approval-of-krazati-adagrasib-as-a-targeted-treatment-option-for-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc-with-a-krasg12c-mutation-301700902.html
https://www.fiercebiotech.com/biotech/kras-battle-heats-mirati-pressures-amgen-keytruda-combo-show-lung-cancer
https://ir.mirati.com/press-releases/press-release-details/2022/Mirati-Therapeutics-Presents-Late-Breaking-Results-Evaluating-Concurrent-Adagrasib-and-Pembrolizumab-in-First-Line-AdvancedMetastatic-Non-Small-Cell-Lung-Cancer-NSCLC/default.aspx
https://endpts.com/mirati-gauging-sale-interest-of-big-pharmas-report/
https://www.natlawreview.com/article/mirati-therapeutics-sues-china-s-inventisbio-99-million-rmb-trade-secret-theft-case
https://www.prnewswire.com/news-releases/mirati-therapeutics-and-aadi-bioscience-partner-to-evaluate-the-combination-of-adagrasib-with-nab-sirolimus-in-patients-with-advanced-non-small-cell-lung-cancer-and-other-solid-tumors-with-a-krasg12c-mutation-301646795.html
https://ir.mirati.com/press-releases/press-release-details/2022/Mirati-Therapeutics-Presents-Late-Breaking-Adagrasib-Monotherapy-and-Combination-Results-in-Advanced-Colorectal-Cancer/default.aspx
https://www.fiercebiotech.com/biotech/its-all-tied-adagrasib-and-lumakras-identical-researcher-says
https://www.fiercebiotech.com/biotech/asco-mirati-cedes-amgens-lumakras-durability-tight-kras-battle
https://www.biospace.com/article/releases/mirati-therapeutics-submits-marketing-authorization-application-to-the-european-medicines-agency-for-investigational-adagrasib-as-a-treatment-for-previously-treated-krasg12c-mutated-non-small-cell-lung-cancer/
https://www.fiercepharma.com/pharma/amgen-s-lumakras-produces-encouraging-results-pancreatic-cancer-though-not-as-dazzling-as
https://ir.mirati.com/press-releases/press-release-details/2022/U.S.-Food-and-Drug-Administration-FDA-Accepts-Mirati-Therapeutics-New-Drug-Application-for-Adagrasib-as-Treatment-of-Previously-Treated-KRASG12C-Mutated-Non-Small-Cell-Lung-Cancer/default.aspx
https://www.fiercebiotech.com/biotech/mirati-s-very-big-drug-adagrasib-at-fda-s-doors-for-lung-cancer-leads-to-41-response-gi
https://www.clinicaltrialsarena.com/news/mirati-verastem-lung-cancer/
https://endpts.com/mirati-sees-more-responses-for-kras-drug-in-keytruda-combo-as-it-angles-for-an-edge-over-amgen/
https://www.fiercebiotech.com/biotech/kras-race-against-amgen-mirati-cmo-and-coo-shown-exit-ahead-fda-drug-approval-request
https://www.fiercebiotech.com/biotech/mirati-sanofi-join-forces-lung-cancer-a-kras-shp2-combo-approach
https://www.fiercepharma.com/pharma/biogen-mirati-mrna-players-merck-s-m-a-shortlist-as-ceo-still-hungry-for-deals-after-11-5b
https://endpts.com/fresh-off-a-meltdown-at-fergene-david-meek-takes-over-at-mirati-with-lead-kras-drug-racing-to-an-approval/
https://www.cancernetwork.com/view/promising-preliminary-data-for-kras-g12c-inhibition-with-adagrasib-is-presented-for-crc
https://www.prnewswire.com/news-releases/mirati-therapeutics-presents-positive-clinical-data-with-investigational-adagrasib-as-monotherapy-and-in-combination-with-cetuximab-in-patients-with-kras-g12c-mutated-colorectal-cancer-301379950.html
Market Place
Share 
